Navigation Links
New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Date:11/10/2007

Data Also Showed That Over a 6 Month Period, Nasacort AQ Did Not Cause

Significant Adrenal Suppression in This Same Age Group

BRIDGEWATER, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting suggests that the intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray may be used safely and effectively to treat children aged 2-5 years old with year-round allergic rhinitis. The same study also showed that during the study, Nasacort AQ did not show a significant effect on adrenal function among a subset of the same patients.

Caused by an allergic reaction to allergens such as house dust, animal dander, or pollen, allergic rhinitis is the most common chronic childhood disease, effecting as many as 40% of all children in the U.S.

A clinical study suggests that Nasacort AQ may present a safe and effective treatment option in children aged 2-5 years with year-round allergic rhinitis

In a multicenter, randomized, double-blind study, Nasacort AQ, given as 1 spray per nostril once daily for 4 weeks, improved combined symptoms of sneezing, nasal itching, discharge, and congestion, compared with placebo in children aged 2-5 years who have had year-round allergic rhinitis for at least one year. Nasacort AQ also showed comparable safety to placebo.

"This study suggests that Nasacort AQ may be used safely and effectively to treat young children who suffer from year-round allergies," said lead investigator Dr. Steven Weinstein of University of California at Irvine College of Medicine.

This study is the first and only randomized, double-blind, placebo-controlled study designed specifically to investigate both the efficacy and safety of an intranasal corticosteroid in this very young age group. A total of 474 patients were randomized to receive either Nasacort AQ or placebo as 1 spray per nostril once daily for 4 weeks. To particip
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. Success of Shape Up Somerville childhood obesity intervention to be presented
5. Survival data presented from phase II study of hormone-resistant prostate cancer patients
6. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
7. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
8. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
9. Horizons AMI trial data to be presented at TCT 2007
10. AMIHOT II trial data presented at TCT
11. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... researchers reveal that sudden, acute episodes of low back ... temperature, humidity, air pressure, wind direction and precipitation. Findings ... journal of the American College of Rheumatology (ACR), indicate ... with higher wind speed or wind gusts, but was ... Health Organization (WHO) nearly everyone experiences low back pain ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... captures heretofore hidden ways that cells are regulated, scientists ... breast cancer cells more likely to metastasize. , What,s ... part by blocking two other proteins that are normally ... disease processes could have unexpected ties. , The ... Nature , points to the possibility of new ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have found ... who are also depressed have difficulty sticking to ... particularly true for women, and screening and brief ... of treatment. The study and its findings are ... , Chronic obstructive pulmonary disease is a ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... line of defence in the threat of bio-terrorism according to ... international team of researchers from Cardiff University and University of ... well be an antidote to Bacillus anthracis more commonly know ... currently drink 165 million cups of tea, and the healing ...
... at Henry Ford Hospital today announced the start of ... international, multi-center clinical trial to explore an investigational treatment ... suffering with advanced emphysema. The study focuses on a ... in the lung for trapped air (one of the ...
... This release is available in French . ... by Universit Laval scientist Marc-Andr Sirard has identified genetic ... best chance of leading to successful pregnancy after in ... success rate of single embryo transfer and diminish the ...
... Angeles, March 12 --Combined positron emission tomography (PET) and ... more effective method to evaluate response to radiation therapy, ... study by researchers at the University of Southern California ... be published in the March issue of the journal ...
... and obesity training, state,s,largest Medicaid managed care plan now ... provide medical professionals the opportunity to become ... Well, Live Well program, CHARLESTON, W.Va., March 12 ... in the country in asthma prevalence,UniCare Health Plan of ...
... TSTF ) a national provider of healthcare and ... the Nasdaq Stock,Market that the Nasdaq Hearings Panel has ... Global Market pending the effectiveness of the,Company,s proposed reverse ... on February 7, 2008. The decision of the Panel ...
Cached Medicine News:Health News:Is a cup of tea really the answer to everything -- even anthrax? 2Health News:Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers 2Health News:Researchers develop a method to select eggs with the best chance of leading to successful pregnancy 2Health News:USC researchers find benefit for lymphoma patients in combined PET-CT scanning 2Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 2Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 3Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 2Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 3
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: